Israeli company bags $4.2m contract to develop cell therapy for radiation poisoning

12 Jul 2023
www.pharmaceutical-technology.com
Orphan DrugDrug ApprovalClinical ResultCell TherapyRadiation Therapy
The US FDA has approved avoplacel’s Investigational New Drug application (IND) and granted it an orphan drug designation for the treatment of radiation sickness in nuclear events. Image Credit: Bohdan Populov / Shutterstock. Israel-based Pluri has signed a three-year $4.2m contract with the US National Institute of Allergy and Infectious Diseases (NIAID) and the US Department of Defense (DoD) to develop its cell therapy avoplacel (PLX-R18) to treat haematopoietic acute radiation syndrome or radiation poisoning. The funding is expected to support avoplacel’s development until marketing approval has been granted by the US Food and Drug Administration (FDA), as per an 11 July announcement. Following that, there are plans to purchase avoplacel as a radiation exposure countermeasure for the US Strategic National Stockpile. Avoplacel is an intramuscular treatment composed of human placenta-derived stromal cells. It is intended to be administered 48 or more hours following exposure to radiation to help counteract radiation’s effect and boost bone marrow and blood cell recovery. The FDA has approved avoplacel’s investigational new drug (IND) application and granted it an orphan drug designation for the treatment of radiation sickness in nuclear events. Pluri CEO Yaky Yanay said: “The current time calls for us to accelerate the development and accessibility of radiation treatments, especially as geopolitical instability rises, and nuclear power plants face the threat of warfare. “Through this strategic contract with NIAID, we believe that we can realise our mission of making PLX-R18 (avoplacel) readily available for emergency preparedness.” Other drugs currently under development for acute radiation sickness include Enzychem Lifesciences’ mosedipimod, New Amsterdam Sciences’ NAS-150, and Statera Biopharma’s entolimod. Avoplacel’s study data In animal model studies, avoplacel showed a marked improvement in survival rates of 97% in the treatment group versus 29% in the control group following exposure to radiation. When used prophylactically, 24 hours to 72 hours before exposure, it resulted in survival rates of 74% and 4% in the treatment and control groups, respectively. There was also an increase in blood cell counts, including white blood cells, platelets, neutrophils, and lymphocytes, which are severely decreased because of radiation sickness. Human studies of avoplacel in patients with incomplete hematopoietic recovery following haematopoietic cell transplantation reported an increase in blood counts and a decreased need for repeated blood transfusions over a 12-month period.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.